Hydrogen peroxide/ATR-Chk2 activation mediates p53 protein stabilization and anti-cancer activity of cheliensisin A in human cancer cells
- PMID: 24553354
- PMCID: PMC3996661
- DOI: 10.18632/oncotarget.1780
Hydrogen peroxide/ATR-Chk2 activation mediates p53 protein stabilization and anti-cancer activity of cheliensisin A in human cancer cells
Abstract
Chiliensisine A (Chel A) as a novel styryl-lactone isolated from Goniothalamus cheliensis Hu has been indicated to be a chemotherapeutic agent in Leukemia HL-60 cells. However, its potential for cancer treatment and the underlying mechanisms are not deeply investigated to the best of our knowledge. Current studies showed that Chel A could trigger p53-mediated apoptosis, accompanied with dramatically inhibition of anchorage-independent growth of human colon cancer HCT116 cells. Further studies found that Chel A treatment resulted in p53 protein stabilization and accumulation via the induction of its phosphorylation at Ser20 and Ser15. Moreover, Chel A-induced p53 protein accumulation and activation required ATR/Chk2 axis, which is distinct from the mechanism that we have most recently identified the Chk1/p53-dependent apoptotic response by Chel A in normal mouse epidermal Cl41 cells. In addition, our results demonstrated that hydrogen peroxide generation induced by Chel A acted as a precursor for all these signaling events and downstream biological effects. Taken together, we have identified the Chel A as a new therapeutic agent, which highlights its potential for cancer therapeutic effect.
Figures






Similar articles
-
Crucial role of c-Jun phosphorylation at Ser63/73 mediated by PHLPP protein degradation in the cheliensisin a inhibition of cell transformation.Cancer Prev Res (Phila). 2014 Dec;7(12):1270-81. doi: 10.1158/1940-6207.CAPR-14-0233. Epub 2014 Oct 3. Cancer Prev Res (Phila). 2014. PMID: 25281487 Free PMC article.
-
Cheliensisin A inhibits EGF-induced cell transformation with stabilization of p53 protein via a hydrogen peroxide/Chk1-dependent axis.Cancer Prev Res (Phila). 2013 Sep;6(9):949-958. doi: 10.1158/1940-6207.CAPR-13-0097. Epub 2013 Jul 12. Cancer Prev Res (Phila). 2013. PMID: 23852422 Free PMC article.
-
Cheliensisin A (Chel A) induces apoptosis in human bladder cancer cells by promoting PHLPP2 protein degradation.Oncotarget. 2016 Oct 11;7(41):66689-66699. doi: 10.18632/oncotarget.11440. Oncotarget. 2016. PMID: 27556506 Free PMC article.
-
ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis.J Biol Chem. 2008 Mar 7;283(10):6572-83. doi: 10.1074/jbc.M707568200. Epub 2007 Dec 27. J Biol Chem. 2008. PMID: 18162465
-
Nitric oxide and p53 in cancer-prone chronic inflammation and oxyradical overload disease.Environ Mol Mutagen. 2004;44(1):3-9. doi: 10.1002/em.20024. Environ Mol Mutagen. 2004. PMID: 15199542 Review.
Cited by
-
Anti-Cancer Activity of a 5-Aminopyrazole Derivative Lead Compound (BC-7) and Potential Synergistic Cytotoxicity with Cisplatin against Human Cervical Cancer Cells.Int J Mol Sci. 2019 Nov 7;20(22):5559. doi: 10.3390/ijms20225559. Int J Mol Sci. 2019. PMID: 31703393 Free PMC article.
-
Divergent behaviors and underlying mechanisms of cell migration and invasion in non-metastatic T24 and its metastatic derivative T24T bladder cancer cell lines.Oncotarget. 2015 Jan 1;6(1):522-36. doi: 10.18632/oncotarget.2680. Oncotarget. 2015. PMID: 25402510 Free PMC article.
-
Hydroxypropyl-β-Cyclodextrin Complexes of Styryllactones Enhance the Anti-Tumor Effect in SW1116 Cell Line.Front Pharmacol. 2020 Apr 22;11:484. doi: 10.3389/fphar.2020.00484. eCollection 2020. Front Pharmacol. 2020. PMID: 32390840 Free PMC article.
-
Additive Protective Effects of Delayed Mild Therapeutic Hypothermia and Antioxidants on PC12 Cells Exposed to Oxidative Stress.Ther Hypothermia Temp Manag. 2021 Jun;11(2):77-87. doi: 10.1089/ther.2019.0034. Epub 2020 Apr 17. Ther Hypothermia Temp Manag. 2021. PMID: 32302519 Free PMC article.
-
Crucial role of c-Jun phosphorylation at Ser63/73 mediated by PHLPP protein degradation in the cheliensisin a inhibition of cell transformation.Cancer Prev Res (Phila). 2014 Dec;7(12):1270-81. doi: 10.1158/1940-6207.CAPR-14-0233. Epub 2014 Oct 3. Cancer Prev Res (Phila). 2014. PMID: 25281487 Free PMC article.
References
-
- Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10–30. - PubMed
-
- Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562–573. - PubMed
-
- Tachibana M, Kawamata H, Fujimori T, Omotehara F, Horiuchi H, Ohkura Y, Igarashi S, Kotake K, Kubota K. Dysfunction of p53 pathway in human colorectal cancer: analysis of p53 gene mutation and the expression of the p53-associated factors p14ARF, p33ING1, p21WAF1 and MDM2. Int J Oncol. 2004;25:913–920. - PubMed
-
- Li CM MQ, Sun HD, Xu B, Tang WD, Zheng HL, et al. A new anti-cancer constituent of Goniothalamus cheliensis. Acta Botanica Yunnanica. 1998;20:102–104.
-
- Zhong L, Li CM, Hao XJ, Lou LG. Induction of leukemia cell apoptosis by cheliensisin A involves down-regulation of Bcl-2 expression. Acta Pharmacol Sin. 2005;26:623–628. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous